Hospital News and Research

RSS

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Red blood cells have the very important role of carrying oxygen from the lungs to the rest of the body; therefore, disorders that affect RBCs can have a significant impact on quality of life. Sickle cell disease and malaria are two common RBC diseases that affect a significant portion of the U.S. and global populations. Sickle cell disease, a genetic blood disorder that causes deformed and dysfunctional red blood cells, affects an estimated 70,000 to 100,000 Americans, while malaria affects approximately 1,500 Americans annually and 190 to 311 million people worldwide.

6 Dec 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.

6 Dec 2010

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

6 Dec 2010

ACAAI allergist experts available to comment on new food allergy guidelines

Food allergy experts from the American College of Allergy, Asthma and Immunology are available to comment as the National Institute of Allergy and Infectious Diseases releases the Guidelines for the Diagnosis and Management of Food Allergy on December 6. The ACAAI was one of more than 30 professional organizations, federal agencies and lay organizations who collaborated on the development of these recommendations.

6 Dec 2010

Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Monthly blood transfusions combined with daily medication to remove the resulting excess iron remains the best approach for reducing the risk of recurrent strokes in young patients with sickle cell anemia, according to a preliminary analysis of a multicenter trial that includes St. Jude Children's Research Hospital.

6 Dec 2010

Oral levetiracetam may be effective in stopping neonatal seizures

Seizures that occur in the first few weeks of life are a major predictor of future adverse neurological outcomes. Currently approved antiepileptic drugs (AEDs) are effective in stopping seizures in less than 50% of these neonatal cases. The approved therapies can also have undesirable side effects.

6 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

Texas gov. Perry backs away from Medicaid dropout threat

Medicaid and the Children's Health Insurance Program are breaking the state's budget, but opting out of the federal programs would have a devastating effect on health care delivery in Texas, according to a state report issued Friday. The report said most of the methods for fixing Medicaid spending in Texas will require acts of Congress, not the Legislature, to give the state greater flexibility in how the programs are run and a greater share of the national Medicaid financing.

6 Dec 2010

Researchers adapt gene chip microarray technology to study glycans

Sugar molecules coat every cell in our bodies and play critical roles in development and disease, yet the components of these "glycans" have been difficult for scientists to study, because of their complexity.

6 Dec 2010

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.

5 Dec 2010

Symposium to highlight aggression nurses experience in workplaces and lives

Nurses will use the National Day of Remembrance and Action on Violence Against Women to shine a spotlight on the aggression nurses and other health-care professionals experience in their workplaces and lives.

4 Dec 2010

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

Hospital for Special Surgery announced the creation of the Center for Musculoskeletal Outcomes and Patient Oriented Research to translate information collected from an extensive patient population into studies that will guide experts in preventing, diagnosing and treating musculoskeletal disorders.

4 Dec 2010

AANS injury prevention tips during winter holiday season

During the winter holiday season there are many warnings in the news about preventing house fires caused by Christmas trees and faulty electrical wiring. There are also warnings about too much merriment leading to alcohol-related motor vehicle accidents. A lesser known fact is the risk of head injury related to hanging and taking down Christmas decorations.

4 Dec 2010

Conference focuses on new molecular, mechanical solutions to improve surgeries

A two-day conference at the University of Chicago Medical Center is designed to offer surgeons a peek at the profession's future by focusing on new molecular and mechanical solutions to three age-old problems: preventing the breakdown of anastomoses (the surgically created connections between blood vessels), improving tissue healing after surgery and developing new tools to test and sharpen surgical skills.

4 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

Wide-scale study of flu vaccine's effectiveness in European children needed

A wide-scale study of the effectiveness of flu vaccine in children is needed in Europe to fully assess the benefits, not only in keeping the kids from getting sick, but limiting the spread of flu to adults.

4 Dec 2010

ETP, EF announce latest grant recipients of New Therapy Grants Program

The Epilepsy Therapy Project and the Epilepsy Foundation today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of two non-profit epilepsy organizations, to advance promising epilepsy research in clinical development.

4 Dec 2010

Healthy People 2020 targets barriers to breastfeeding

For the first time, the barriers to breastfeeding are being addressed at the highest level of government. With the release today of Healthy People 2020, the U.S. Department of Health and Human Services has targeted the new 10-year goals for our nation's health - and supporting breastfeeding is prominent among them.

4 Dec 2010